TNFα contributes to the antitumor activity of a bispecific, trifunctional antibody

Anticancer Research

Volumn 21, Issue 5, 2001, Pages 3499-3503

  Zeidler, Reinhard ^a   Mayer, Anna ^a   Gires, Olivier ^a   Schmitt, Bärbel ^a   Mack, Brigitte ^a   Lindhofer, Horst ^a   Wollenberg, Barbara ^a   Walz, Annette ^a  

^a Department of Head Surgery ^*  (Germany)

Author keywords

Bispecific antibody; Cancer; TNF ; Trifunctional

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; TRIOMAB; TUMOR NECROSIS FACTOR ALPHA; CELL ADHESION MOLECULE; RECOMBINANT PROTEIN; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN GA733; TUMOR-ASSOCIATED ANTIGEN GA733;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOLECULAR RECOGNITION; MONONUCLEAR CELL; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL; BIOSYNTHESIS; CELL CULTURE; HEAD AND NECK TUMOR; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; PASSIVE IMMUNIZATION; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, BISPECIFIC; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNIZATION, PASSIVE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035528821     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
2. Bispecific antibodies target operationally tumorspecific antigens in two leukemia relapse models
3. Phase 1a/1b trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu
4. Bispecific monoclonal antibody therapy of B-cell malignancy
5. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease
6. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody
7. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy
8. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody
9. In vivo targeting of human neuroblastoma xenograft by anti-GD2/anti-Fc gamma RI (CD64) bispecific antibody
10. Triggering FCalpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy
11. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing
12. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells
13. Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody
14. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies
15. Characteristics, of a human cell line transformed by DNA from human adenovirus type 5
16. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity
17. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
18. CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma
19. Immunomodulatory effects of intravenous BIS-1 F(ab′) 2 administration in renal cell cancer patients
20. Genetic instability and darwinian selection in tumours